Atika Capital Management LLC Prothena Corp Public LTD CO Transaction History

Atika Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$48.26 - $78.59 $2.36 Million - $3.84 Million	48,922 Added 100.71%	97,500 $6.66 Million
Q1 2023 May 12, 2023	SELL	$46.97 - $58.27 $2 Million - $2.48 Million	-42,600 Reduced 46.72%	48,578 $2.35 Million
Q4 2022 Feb 13, 2023	BUY	$52.05 - $65.0 $4.75 Million - $5.93 Million	91,178 New	91,178 $5.49 Million
Q4 2021 Feb 11, 2022	SELL	$42.11 - $73.26 $9.46 Million - $16.5 Million	-224,600 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$48.2 - $78.89 $453,080 - $741,566	-9,400 Reduced 4.02%	224,600 $16 Million
Q2 2021 Aug 12, 2021	BUY	$21.63 - $57.65 $4.67 Million - $12.5 Million	216,094 Added 1206.82%	234,000 $12 Million
Q1 2021 May 14, 2021	BUY	$11.0 - $28.24 $196,966 - $505,665	17,906 New	17,906 $450,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $714M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Atika Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Atika Capital Management LLC with notifications on news.